jeudi 18 octobre 2018

Onco Actu du 18 octobre 2018


1. Biologie

A Bad Influence: The Interplay between Tumor Cells and Immune Cells [Huntsman Cancer Institute]

2. Etiologie

Why Oral Cancer Threatens Men [Scientific American]

2.5 Etiologie - Gènes

Genetic Differences in Prostate Cancer Pinpointed in Black Men [Renal & Urology News]

4.3 Dép., diag. & prono. - Industriels

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Pfizer’s TALZENNA® (talazoparib) [Myriad Genetics]

5.1 Traitements - Pré-clinique

Vast Leukemia Dataset Could Help Researchers Match Therapies to Patients [HHMI]

5.12 Immunothérapies

Cartoons offer a peek into cancer immunotherapy — and scientists’ minds [STAT]

5.12.8 Immunothérapies - Economie

We can now customize cancer cures, tumor by tumor [MIT Technology Review]

5.2 Pharma

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL) [AbbVie]

Pfizer bags an FDA OK for PARP player talazoparib — now the hard part begins [EndPoints]

5.2.1 Pharma - Partenariats

Foundation Medicine Announces Strategic Collaboration with Major Pharmaceutical Company [Foundation Medicine]

5.3 Traitements - FDA, EMA, NICE...

FDA lists 205 molecular targets for pediatric cancer research [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA Approves a New PARP Inhibitor for BRCA-mutant Breast Cancer [Cancer Research Catalyst]

5.6 ESMO

ESMO advocacy for patient-centred care takes on global dimension [ESMO Press Release]

5.9.1 ASTRO

High-dose radiation therapy substantially improves survival in patients once thought to be incurable [ASTRO]

6.1 Observation

How healthy will we be in 2040? [IHME]

6.10.1 Politiques (USA)

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided [STAT]

6.14 Prix Nobel

Nobel Prize 2018: how the winning chemistry technique helped generate new cancer treatments [Cancer Research UK]

6.8 Communication

Problematic PR releases: As evidence lags on proton therapy, hospitals lure patients with anecdotes and high-tech appeals [HealthNewsReview]